v3.25.4
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Total income and other revenues $ 2,378,193 $ 2,263,576 $ 2,354,554
Operating (income)/expense      
Provision for changes in expected cash flows from financial royalty assets (295,838) 732,461 560,656
Provision for credit losses on unfunded commitments 89,032 0 0
Research and development funding expense 452,000 2,000 52,000
General and administrative expenses (includes $290,890, $3,224, and $3,302 of share-based compensation expense for the years ended December 31, 2025, 2024 and 2023, respectively; see Note 4) 573,481 236,671 249,748
Total operating expense, net 818,675 971,132 862,404
Operating income 1,559,518 1,292,444 1,492,150
Other (income)/expense      
Equity in earnings of equity method investees (29,089) (29,611) (28,882)
Interest expense 307,664 225,512 187,187
Losses on derivative financial instruments 0 6,000 2,290
Losses/(gains) on equity securities 21,852 (39,549) (87,139)
Gains on available for sale debt securities (45,859) (154,906) (230,840)
Interest income (33,591) (47,343) (72,291)
Other non-operating expenses, net 14,349 1,528 21,737
Total other expense/(income), net 235,326 (38,369) (207,938)
Consolidated net income before tax 1,324,192 1,330,813 1,700,088
Income tax expense 0 0 0
Consolidated net income 1,324,192 1,330,813 1,700,088
Net income attributable to non-controlling interests 553,245 471,830 565,254
Net income attributable to Royalty Pharma plc $ 770,947 $ 858,983 $ 1,134,834
Earnings per Class A ordinary share:      
Basic (in dollars per share) $ 1.79 $ 1.92 $ 2.54
Diluted (in dollars per share) $ 1.78 $ 1.91 $ 2.53
Weighted average Class A ordinary shares outstanding:      
Basic (in shares) 429,801 448,185 447,601
Diluted (in shares) 564,455 594,108 602,900
Income from financial royalty assets      
Total income and other revenues $ 2,261,152 $ 2,149,422 $ 2,197,754
Other royalty income and revenues      
Total income and other revenues $ 117,041 $ 114,154 $ 156,800